Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...
Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...
In the third quarter, Lilly earned $7.02 per share on an adjusted basis, far above the $5.69 analysts were expecting, ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.
The site will also help make treatments for heart disease, diabetes, cancer, and autoimmune disorders areas where Lilly has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback